Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXR), compositions comprising any of such novel compounds, methods of using these compounds or compositions as medicaments for prevention or treatment of diseases or disorders related to liver X receptor (LXR), as well as methods of preparing these LXR modulators and using them in the manufacture of medicaments.
March 14, 2014
Date of Patent:
December 5, 2017
Bristo-Myers Squibb Company, Exelixis Patent Company LLC
Ellen K. Kick, Mandar Bodas, Raju Mohan, Meriah Valente, Nicholas Wurtz, Sharanabasappa Patil
Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula
where n is 0 or 1; X is H or CN;
Y is N, NH or O;
Z is CH2 when Y is O or N—H, with Y—Z forming a single bond, and Z is CH when Y is N, with Y—Z forming a double bond;
and wherein R1, R2, R3 and R4 are as described herein.
A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.